Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed in myocardial perfusion imaging to assess blood flow to the heart muscle, aiding the evaluation of coronary artery disease in adult patients undergoing cardiac stress testing.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic imaging centres and procurement teams worldwide, with adherence to regulatory standards and cold‑chain logistics where required, ensuring product integrity.

Myoview (tetrofosmin) is used in myocardial perfusion imaging to evaluate coronary artery disease.

Coronary artery disease: helps visualize perfusion defects to assess severity. Myocardial ischemia: enables detection of stress‑induced perfusion abnormalities. Myocardial viability: assists in distinguishing viable from scarred myocardium for revascularization planning.

Adverse reactions may occur after administration of Myoview.

Common Side Effects: - Nausea - Headache - Flushing - Injection site pain - Dizziness - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension - Cardiac arrhythmia - Acute respiratory distress - Severe allergic skin reactions

Use of Myoview requires careful consideration of patient-specific factors.

Pregnancy: safety not established; avoid unless essential. Breastfeeding: unknown; weigh potential risks. Renal impairment: use with caution; monitor renal function. Allergy: assess for hypersensitivity to technetium‑99m or tetrofosmin. Concurrent cardiac stress agents: follow protocol to avoid interference. Store at ambient temperature: keep in original container, protect from light and moisture.

Myoview may interact with other agents that affect myocardial uptake or radiotracer distribution.

Major Interactions (Avoid): - Thyroid hormone therapy: may alter radiotracer uptake. - Other radiopharmaceuticals: avoid concurrent administration.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may modify heart‑rate response during stress testing. - Calcium channel blockers: may influence myocardial blood flow. - Vasodilators (e.g., dipyridamole): adjust timing to prevent overlapping effects.